Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China

Overview of attention for article published in Frontiers in immunology, May 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland

Article in Frontiers in Pharmacology (July 2024)

Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review

Article in BMC Cancer (March 2024)

Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer

Article in Current Medical Research and Opinion (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.